Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms

被引：0
|
作者：
Johnson, Toby
Xu, Chun-fang
Choueiri, Toni K.
Deen, Keith C.
Xue, Zhengyu
Bartlett-Pandite, Arundathy N.
Carpenter, Christopher
Motzer, Robert John
机构：
[1] GlaxoSmithKline, Uxbridge, Middx, England
[2] GlaxoSmithKline, Harlow, Essex, England
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4569
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Do UGT1A1 and HMOX1 gene promoter polymorphisms increase the risk of hyperbilirubinemia and gallstones in patients with hereditary spherocytosis?
    Warang, Prashant
    Devendra, Rati
    D'Silva, Selma
    Chiddarwar, Ashish
    Kedar, Prabhakar
    Ghosh, Kanjaksha
    Colah, Roshan
    Mukherjee, Malay B.
    ANNALS OF HEMATOLOGY, 2015, 94 (01) : 169 - 171
  • [42] Do UGT1A1 and HMOX1 gene promoter polymorphisms increase the risk of hyperbilirubinemia and gallstones in patients with hereditary spherocytosis?
    Prashant Warang
    Rati Devendra
    Selma D’Silva
    Ashish Chiddarwar
    Prabhakar Kedar
    Kanjaksha Ghosh
    Roshan Colah
    Malay B. Mukherjee
    Annals of Hematology, 2015, 94 : 169 - 171
  • [43] The Effect of UGT1A1 Promoter Polymorphism in the Development of Hyperbilirubinemia and Cholelithiasis in Hemoglobinopathy Patients
    AlFadhli, Suad
    Al-Jafer, Hassan
    Hadi, Mays
    Al-Mutairi, Mashael
    Nizam, Rasheeba
    PLOS ONE, 2013, 8 (10):
  • [44] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2017, 37 (01) : 35 - 42
  • [45] Linkage disequilibrium of UGT1A1*6 and UGT1A1*28 in relation to UGT1A6 and UGT1A7 polymorphisms
    Urawa, Naohito
    Kobayashi, Yoshinao
    Araki, Jun
    Sugimoto, Ryosuke
    Iwasa, Motoh
    Kaito, Masahiko
    Adachi, Yukihko
    ONCOLOGY REPORTS, 2006, 16 (04) : 801 - 806
  • [46] Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
    Wenning, L. A.
    Petry, A. S.
    Kost, J. T.
    Jin, B.
    Breidinger, S. A.
    DeLepeleire, I.
    Carlini, E. J.
    Young, S.
    Rushmore, T.
    Wagner, F.
    Lunde, N. M.
    Bieberdorf, F.
    Greenberg, H.
    Stone, J. A.
    Wagner, J. A.
    Iwamoto, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (06) : 623 - 627
  • [47] UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
    Meza-Junco, Judith
    Chu, Quincy S. -C.
    Christensen, Olaf
    Rajagopalan, Prabhu
    Das, Soma
    Stefanyschyn, Ruslan
    Sawyer, Michael B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 1 - 4
  • [48] Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population
    Chalirmporn Atasilp
    Janjira Kanjanapipak
    Jaratdao Vichayaprasertkul
    Pimonpan Jinda
    Rawiporn Tiyasirichokchai
    Pornpen Srisawasdi
    Chatchay Prempunpong
    Monpat Chamnanphon
    Apichaya Puangpetch
    Natchaya Vanwong
    Suwit Klongthalay
    Thawinee Jantararoungtong
    Chonlaphat Sukasem
    BMC Pediatrics, 22
  • [49] The relationship between hyperbilirubinemia and the promoter region and first exon of UGT1A1 gene polymorphisms in Vietnamese newborns
    Nguyen, Tien-Thanh
    Zhao, Wei
    Yang, Xi
    Zhong, Dan-Ni
    PEDIATRIC RESEARCH, 2020, 88 (06) : 940 - 944
  • [50] 211 G to A variation of UGT1A1 and severe neonatal hyperbilirubinemia
    Lin, Yu-Jung
    Tsao, Po-Nien
    PEDIATRICS AND NEONATOLOGY, 2018, 59 (01): : 106 - 107
12345